Eva Hellmis

856 total citations
17 papers, 201 citations indexed

About

Eva Hellmis is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Eva Hellmis has authored 17 papers receiving a total of 201 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Eva Hellmis's work include Prostate Cancer Treatment and Research (9 papers), Radiopharmaceutical Chemistry and Applications (5 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Eva Hellmis is often cited by papers focused on Prostate Cancer Treatment and Research (9 papers), Radiopharmaceutical Chemistry and Applications (5 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Eva Hellmis collaborates with scholars based in Germany, France and United States. Eva Hellmis's co-authors include Silke Schwarz, G. H. Jacobi, Hans Konrad Biesalski, Ute C. Obermüller-Jevic, Boris Hadaschik, Henrik Walter, H. Madersbacher, S. Alloussi, P.R. Bock and Gerd Mürtz and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Nutrition and Annals of Oncology.

In The Last Decade

Eva Hellmis

15 papers receiving 194 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eva Hellmis Germany 5 57 56 37 35 28 17 201
Jae Hyung You South Korea 9 9 0.2× 32 0.6× 70 1.9× 21 0.6× 20 0.7× 20 316
T. Pejcic Serbia 10 28 0.5× 113 2.0× 64 1.7× 45 1.3× 24 0.9× 58 354
Neil Harris United Kingdom 8 50 0.9× 113 2.0× 59 1.6× 97 2.8× 6 0.2× 16 318
Junjun Li China 9 6 0.1× 45 0.8× 56 1.5× 16 0.5× 10 0.4× 37 314
Gerold Stark United States 3 14 0.2× 194 3.5× 69 1.9× 34 1.0× 5 0.2× 5 395
T. Senge Germany 7 14 0.2× 128 2.3× 83 2.2× 36 1.0× 4 0.1× 26 337
Fatemeh Masjedi Iran 9 10 0.2× 9 0.2× 35 0.9× 3 0.1× 16 0.6× 33 267
Alina Smalinskienė Lithuania 11 19 0.3× 3 0.1× 81 2.2× 20 0.6× 12 0.4× 34 347
Swapnil Shah United States 8 58 1.0× 3 0.1× 76 2.1× 22 0.6× 5 0.2× 18 283
Gareth Brock United Kingdom 6 16 0.3× 9 0.2× 117 3.2× 14 0.4× 2 0.1× 13 530

Countries citing papers authored by Eva Hellmis

Since Specialization
Citations

This map shows the geographic impact of Eva Hellmis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Hellmis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Hellmis more than expected).

Fields of papers citing papers by Eva Hellmis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva Hellmis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Hellmis. The network helps show where Eva Hellmis may publish in the future.

Co-authorship network of co-authors of Eva Hellmis

This figure shows the co-authorship network connecting the top 25 collaborators of Eva Hellmis. A scholar is included among the top collaborators of Eva Hellmis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eva Hellmis. Eva Hellmis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
2.
3.
Boegemann, Martin, Mostefa Bennamoun, Louis Marie Dourthe, et al.. (2025). Final analysis of ArtemisR, a European real-world retrospective study of apalutamide for the treatment of patients with metastatic hormone-sensitive prostate cancer. BMC Cancer. 25(1). 1119–1119. 1 indexed citations
4.
5.
6.
Sonpavde, Guru, Cora N. Sternberg, Yohann Loriot, et al.. (2022). Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma. European Journal of Cancer. 163. 55–65. 5 indexed citations
7.
König, Frank, et al.. (2022). Retrospektive Versorgungsstudie von d-uo zur Therapie des mCRPC mit Radium-223-dichlorid. Aktuelle Urologie. 53(6). 511–516. 1 indexed citations
8.
Hadaschik, Boris & Eva Hellmis. (2021). Therapie des nicht-fernmetastasierten CRPC. Der Urologe. 60(6). 753–759. 3 indexed citations
9.
10.
11.
Grünwald, Viktor, Carsten Grüllich, Philipp Ivanyi, et al.. (2020). A randomized phase II trial comparing switch to nivolumab with TKI continuation after 12 weeks of TKI induction therapy in metastatic renal cell carcinoma patients (NIVOSWITCH).. Journal of Clinical Oncology. 38(6_suppl). 678–678. 2 indexed citations
12.
Ohlmann, Carsten‐Henning, Eva Hellmis, H. Suttmann, et al.. (2019). Abiraterone acetate plus prednisone (AA+P) without continuing LHRH-therapy in patients with metastatic chemotherapy: Naive castrations-resistant prostate cancer—Results from the SPARE-trial (NCT02077634).. Journal of Clinical Oncology. 37(15_suppl). 5046–5046. 2 indexed citations
13.
Ohlmann, Carsten‐Henning, Eva Hellmis, H. Suttmann, et al.. (2019). Sparing androgen-deprivation therapy upon treatment with abiraterone in patients with chemotherapy-naive castration-resistant prostate cancer: Results from the SPARE-trial (NCT02077634). European Urology Supplements. 18(1). e1390–e1391. 1 indexed citations
14.
15.
Schwarz, Silke, et al.. (2008). Lycopene Inhibits Disease Progression in Patients with Benign Prostate Hyperplasia. Journal of Nutrition. 138(1). 49–53. 107 indexed citations
16.
Hellmis, Eva. (2008). Sexual problems in males with epilepsy—An interdisciplinary challenge!. Seizure. 17(2). 136–140. 22 indexed citations
17.
Alloussi, S., Maria Heinrich, Eva Hellmis, et al.. (2006). PROPIVERINE COMPARED TO OXYBUTYNIN IN CHILDREN WITH IDIOPATHIC DETRUSOR OVERACTIVITY – ARE EFFICACY AND TOLERABILITY COMPARABLE?. European Urology Supplements. 5(2). 304–304. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jae Hyung You Breakdown of academic impact, for papers by T. Pejcic Breakdown of academic impact, for papers by Neil Harris Breakdown of academic impact, for papers by Junjun Li Breakdown of academic impact, for papers by Gerold Stark Breakdown of academic impact, for papers by T. Senge Breakdown of academic impact, for papers by Fatemeh Masjedi Breakdown of academic impact, for papers by Alina Smalinskienė Breakdown of academic impact, for papers by Swapnil Shah Breakdown of academic impact, for papers by Gareth Brock
Rankless by CCL
2026